September 2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012.  Fiscal Year and Recent Highlights Bremelanotide development for …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results Read More »

CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).  Database lock is expected by the end of September and top-line trial results are expected …

Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial Read More »

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued …

Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca Read More »

CRANBURY, N.J., Sept.  6, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2012 financial results on Tuesday, September 11, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 11, …

Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012 Read More »